PGR and breast cancer: BC may either show primary PgR negative phenotype (i.e., negative PgR expression in tumor sample assessed before systemic therapy), lose PgR expression during neoadjuvant treatment (assessed in the postsurgical specimen), or acquire PgR negative phenotype in local relapse or metastasis.